New Hope for Tough Ovarian Cancer Cases

Big news for ovarian cancer research: the FDA just fast-tracked INX-315, a new drug aimed at patients whose tumors resist standard treatments. This CDK2 inhibitor targets a genetic change (CCNE1 amplification) that makes some cancers extra stubborn. Early trials are underway, and if things go well, this could mean a real breakthrough for people running out of options. Fingers crossed for more good news soon! #OvarianCancer #CancerResearch #FDAFastTrack #ClinicalTrials #MedicalBreakthrough #Health